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268 C.-P. Liu et al.that KMUP-1 enhanced eNOS, soluble guanylate cyclase, and protein kinase G levels, and
reduced ET-1 expression and inactivated Rho kinase II (ROCKII) in MCT-treated lung tissue over
long-term administration. In MCT-treated rats, KMUP-1 decreased plasma ET-1 on Day 21.
KMUP-1 (3.6 mg/kg) maximally appeared at 0.25 hours in the plasma and declined to basal
levels within 24 hours after sublingual administration. In isolated PA of MCT-treated rats,
compared with control and pretreatment with L-NG-nitroarginine methyl ester (100 mM),
KMUP-1 (0.1e100 mM) inhibited ET-1 (0.01 mM)-induced vasoconstriction. Endothelium-
denuded PA sustained higher contractility in the presence of KMUP-1. In a 24-hour culture of
smooth muscle cells (i.e., PA smooth muscle cells or PASMCs), KMUP-1 (0.1e10 mM) inhibited
RhoA- and ET-1-induced RhoA activation. KMUP-1 prevented MCT-induced PAH, PA wall thick-
ening, and RVH by enhancing eNOS and suppressing ET-1/ROCKII expression. In vitro, KMUP-1
inhibited ET-1-induced PA constriction and ET-1-dependent/independent RhoA activation of
PASMCs. In summary, KMUP-1 attenuates ET-1-induced/ET-1-mediated PA constriction, and
could thus aid in the treatment of PAH caused by MCT.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
This study investigated the role of endothelin-1 (ET-1) in
monocrotaline (MCT)-induced rat pulmonary artery (PA)
constriction, chronic PA hypertension (PAH), and right
ventricular hypertrophy (RVH), as well as the results of
treatment with KMUP-1. ET-1 is involved in RhoA activation
and Rho kinase (ROCK) expression in hypoxic PAH, but its
expression is less clear in MCT-induced PAH. In previous
studies, KMUP-1 inhibited angiotensin II (Ang II)-induced
Ca2þ influx and contraction of pulmonary vascular smooth
muscle cells. KMUP-1 has been reported to inhibit PAH
partly through the serotonin (5-hydroxytryptamine or 5-HT)
pathway [1,2]. ET-1, Ang II, catecholamine, and 5-HT can
all mediate pulmonary arterial RhoA/ROCK activation by
nonspecific G-protein coupled receptors (GPCRs) [1e4]. To
date, bosentan is the representative PAH inhibitor for
inhibiting ET-1-mediated response in the clinic. At present,
no competitors of bosentan are more effective for inhibit-
ing PAH. Antagonists of nonspecific GPCRs, including those
involving the ET-1 receptor, with NO/endothelial nitric
oxide synthase (eNOS)-enhancing activity may be alterna-
tively used instead of, or in combination with, bosentan or
sildenafil for inhibiting ET-1-mediated PA constriction and
PAH caused by MCT.
PAH is a fatal disease characterized by increased pulmo-
nary vascular pressure and progressive structural remodeling
in the PA, leading to RV failure and premature death. In the
development of PAH, altered production of various endo-
thelial vasoactive mediators such as NO, prostacyclin, ET-1,
5-HT, chemokines, and thromboxane had been increasingly
recognized in patients [5]. Among these mediators, ET-1
released from the endothelium, leading to PA vasoconstric-
tion and cell proliferation, is mainly involved in the patho-
genesis of endothelial dysfunction [6].
Therefore, we measured the expression of colocalized
enzyme and protein biomarkers such as eNOS, soluble
guanylate cyclase (sGC), protein kinase G (PKG), ROCKII,
and ET-1 in lung tissues from MCT-treated rats with and
without treatment with KMUP-1. Regulation of upstream
eNOS, sGC, and PKG expression and downstream RhoA/ROCK activation in the cyclic guanosine monophosphate
(cGMP)-signaling pathway affects vascular contractility and
resistance [7]. Initial activation of eNOS in the endothelium
to release NO provides smooth muscle relaxation through
the cGMP/ROCK pathway, and colocalized eNOS, sGC, and
PKG expression in the PA is important for inhibiting PAH
[1,8e10]. However, the relationship between ET-1 and
eNOS/sGC/PKG/RhoA expression in PAH treated with KMUP-
1 remains to be investigated. We hypothesized that pul-
monary colocalized ET-1, RhoA, and eNOS expression or
activation of GPCRs are the major therapeutic targets in
the treatment of PAH.
To date, statins, ROCK inhibitors, and the cGMP-
enhancing phosphodiesterase 5A (PDE-5A) inhibitor silden-
afil have been described as beneficial for treating PAH
[11e17]. Unfortunately, sildenafil requires combination
therapy for the treatment of children’s PAH [18]. More
effective agents for treating PAH by inhibiting the GPCRs
agonist ET-1/Ang II/5-HT and enhancing NO/eNOS are ur-
gently needed for patients. Statins might exert pleiotropic
effects by inhibiting small guanosine triphosphate (GTP)-
binding proteins to enhance eNOS expression and decrease
the transcription of prepro ET-1 messenger RNA (mRNA),
resulting in the reduction of endothelial ET-1 [19]. The
pleiotropic effects of statins encouraged us to search for a
nonstatin molecule that could increase eNOS and reduce
ET-1 expression of PA endothelium in lung tissue, thereby
inhibiting ET-1 release-mediated PAH caused by MCT and
associated hypoxia [20e22].
KMUP-1 is known to enhanceeNOS/cGMP in various animal
tissues [23e25]. In comparison, sildenafil enhances the
activation of cGMP-dependent protein kinase (i.e., PKG) by
inhibiting PDE-5A, which separately suppresses RhoA acti-
vation and cell proliferation [26]. Notably, bosentan and
sildenafil have been combined to achieve full inhibition of
PAH, suppressing 5-HTand ET-1 [27,28]. However, it has been
argued that eNOS expression can be potentiated without
reduced expression of PDE-5A in PAH [1,17]. 5-HT plays an
important role in PAH [5]. Whether KMUP-1 suppresses ET-1,
in addition to inhibiting pulmonary 5-HT, in PAH remains
unclear. In this study, the effects of KMUP-1 on MCT-induced
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and eNOS in PA smoothmuscle cells (PASMCs) were examined
to expose the role of ET-1 in MCT-induced PAH [29].
Methods
Compounds
KMUP-1$HCl (7-{2-[4-(2-chlorobenzene)piperazinyl]ethyl}-
1,3-dimethylxanthine$HCl) was synthesized from KMUP-1 in
our laboratory [1]. Sildenafil was supplied by Cadila
Healthcare Ltd. (Maninagar, Gujarat, India). (3R,4 R,5R,
13aR,13bR)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,10,12,13,
13a,13b-octahydro-2H-[1,6] dioxacycloundecino[2,3,4-gh]
pyrrolizine-2,6(3H)-dione (MCT) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). (þ)-Trans-4-[1(R)-
aminoethyl]-N-(4-pyridyl) cyclohexane-1-carboxamide
(Y27632) was purchased from Cayman Chemical Co.
(Ann Arbor, MI, USA). ET-1 was obtained from Peptide
Institute Inc. (Osaka, Japan).
Animals
All experimental procedures were approved by the Animal
Center of Kaohsiung Medical University (KMU; Kaohsiung,
Taiwan). The protocol for this study was approved by KMU
for submission to this journal by the Institutional Review
Board. In this study, adult male Wistar rats weighing
200e250 g received a single subcutaneous injection of MCT
(60 mg/kg) or vehicle and were allowed 21 days to develop
PAH. A sublingual preparation of KMUP-1 (2.5 mg/kg/day/
25 mL propylene glycol) was applied by micropipette to the
sublingual cavity. Micropipette application of KMUP-1
required less than 1 minute and analgesia was not
needed. The rats were divided into four experimental
groups, namely, Group 1 (normal controls), Group 2 (MCT
treated), Group 3 (MCT-treated rats receiving KMUP-1), and
Group 4 (MCT-treated rats receiving sildenafil).
Hemodynamic measurements of mean pulmonary
arterial pressure and mean artery blood pressure
Measurements of mean pulmonary arterial pressure (MPAP),
heart rate, and mean artery blood pressure (MABP) were
carried out in 10-week-old male Wistar rats anesthetized
with urethane [1.25 g/kg, intraperitoneally (i.p.)]. The
MABP and heart rates were recorded from the femoral ar-
tery. MPAP was recorded from the PA of open-chest rats
using a pressure transducer (Model P50; Gould, Oxnard, CA,
USA) connected to a Pressure Processor Amplifier (Model
13-4615-52). A femoral vein was cannulated and heparin-
ized for intravenous administration of normal saline. KMUP-
1 and sildenafil (2.5 mg/kg/day) were administered sub-
lingually. The animals breathed spontaneously. Body tem-
perature was maintained at 37C.
Isometric force of PAs
Based on our previous method, the isometric force of iso-
lated rat PAs was measured [1]. In brief, Wistar rats wereeuthanized with an overdose of sodium pentobarbital
(60 mg/kg, i.p.) prior to performing the open-chest surgery.
The main PA was cut into 2e3-mm rings, suspended under
isometric conditions, and connected to a force transducer
as previously described (Model 7004; Ugo Basile, Comerio,
Varese, Italy) to measure the constriction caused by ET-1
(0.01 mM).
The PA ring preparations isolated from rats pretreated
with vehicle control (Eþ), denuded PA (E), MCT, and L-NG-
nitroarginine methyl ester (L-NAME; 100 mM) were stretched
to a basal tension of 1 g and allowed to equilibrate for
60e90 minutes. After equilibration, the PA rings were
constricted with ET-1 to prime the tissues and check the
functionality of the endothelium (at least 80% relaxation in
response to acetylcholine 1 mM). Once the contractile
response to ET-1 reached a stable tension level, KMUP-1
(0.1e100 mM) was cumulatively added to the organ bath
preincubated with ET-1 for 15 minutes. The effect of KMUP-
1 on NOS was also studied in vessels preincubated with the
NOS inhibitor L-NAME (100 mM) 20 minutes prior to the
application of ET-1. In some experiments, the endothelium
was denuded by inserting the tweezers into the lumen and
rolling the PA ring back and forth five times to prepare
endothelium-denuded (E) PA for comparison with the
response of endothelium-intact (Eþ) PA to ET-1.
The percentage of relaxation was estimated using the
following equation:
Relaxation ð%ÞZmaximal constriction relaxation level
maximal level basel level
 100
½1
Data were obtained from ET-1-induced maximal con-
tractile responses to the PA. To examine the mechanism of
action of KMUP-1 on MCT-treated endothelium, the PA
tension of the non-MCT treatment control (Group 1) was
compared with the pretreatment of groups with L-NAME or
MCT.
Western blotting analysis
To measure protein expression levels, the total proteins
were extracted and Western blotting analyses were per-
formed as described previously [1]. The eNOS, sGC1a, PKG,
RhoA, ROCKII, and ET-1 expression in lung tissues after
KMUP-1 and sildenafil administration were measured from
the four experimental groups of rats. Mouse or rabbit
monoclonal antibodies to eNOS (Millipore, Temecula, CA,
USA), sGC1a (Sigma-Aldrich), PKG (Calbiochem, San Diego,
CA, USA), RhoA (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), ROCKII (Millipore), ET-1 (Abcam, London, UK), and
the loading control protein b-actin (Sigma-Aldrich) were
used in the Western blot analyses. Whole right lung tissues
of experimental rats were isolated and cut into small chips
to extract protein as described previously [1]. The protein
extract was then boiled in a ratio of 5:1 with sample buffer
[Tris 100 mM, pH 6.8, glycerol 20%, sodium dodecyl sulfate
(SDS) 4%, and bromophenol blue 0.2%]. Electrophoresis was
performed using 10% SDSepolyacrylamide gel (2 hours,
100 V, 40 mA, 20-mg protein per lane). The separated pro-
teins were transferred to polyvinylidene difluoride
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the nonspecific immunoglobulin G (IgG; 90 minutes, 100 V)
and incubated for 1 hour with specific antibody. The blot
was then incubated with antimouse or antigoat IgG linked
to alkaline phosphatase (1:1000) for 1 hour. Immunoreac-
tive bands were visualized using horseradish peroxidase-
conjugated secondary antibodies and subsequently
enhanced chemiluminescence for the detection of the
specific antigen. The intensity of the bands was measured
by densitometry.
Preparation of PASMCs
MCT-treated or nontreated rats were killed with pento-
barbital sodium (60 mg/kg). For culturing PA PASMCs, the PA
rings were gently separated from the underlying connective
tissue and then chopped and placed into a dish and incu-
bated with Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 0.24% NaHCO3, and 1%
penicillin/streptomycin at 37C in a humidified atmosphere
of 5% CO2/95% air. The culture medium was changed every
3 days and cells were subcultured until confluence. Primary
cultures of two to four passages were used in the experi-
ments. Cells were examined by immunofluorescence
staining for b-actin (Sigma-Aldrich) to confirm the purity of
the PASMCs. Over 95% of the cell preparations were found
to be composed of smooth muscle cells.
RhoA activation of PASMCs
RhoA activation was determined using an affinity precipi-
tation assay, which binds only the active GTP-bound form of
Rho. In brief, subconfluent PASMCs were grown to approx-
imately 85e90% confluence and the cells were exposed to
KMUP-1 (0.1 mM, 1 mM, and 10 mM) for 24 hours and to ET-1
(0.01 mM) for 30 minutes with 10% fetal bovine saline at
37C prior to adding lysis buffer (25 mM hydroxyethyl
piperazineethanesulfonic acid, pH 7.5, 150 mM NaCl, 1%
IGEPAL CA-630, 10 mM MgCl2, 1 mM ethylenediaminetetra-
acetic acid and 10% glycerol, 1 mg/mL aprotinin, 10 mg/mL
leupeptin, and 1 mM Na3VO4) for 15 minutes at 4C. Cell
lysates were clarified by centrifuging (13,000g at 4C) for
10 minutes. Equal volumes of lysates were incubated with
agarose-conjugated rhotekin Rho-binding domain for
45 minutes at 4C, and then washed three times with lysis
buffer. Agarose beads were boiled in SDS-polyacrylamide
gel electrophoresis sample buffer to release active RhoA,
and the sample was resolved on a 12% polyacrylamide gel
followed by immunoblotting with anti-RhoA (Clone 55).
Hematoxylineeosin staining
The right lobes of the rat lungs and the heart of six rats from
each group were cut and soaked in formalin, dehydrated
through graded alcohols, and embedded in paraffinwax. The
lung-tissue specimens fixed with formalin were embedded in
paraffin, cut into 4-mm-thick sections and subjected to
hematoxylineeosin (H&E) staining prior to performing light
microscopic examination. The histopathological changes
were evaluated in terms of the thickening of the medial wall
of the small intrapulmonary arteries. In heart tissues, 4-mmparaffin sections were cut from paraffin-embedded tissue
blocks. The tissue sections were deparaffinized by
immersing them in xylene and rehydrated as described
previously [1]. For H&E staining, the slices were dyed with
H&E. After gentle rinsing with water, each slide was dehy-
drated through graded alcohols. Finally, they were soaked
twice in xylene. Photomicrographs were obtained using
Eclipse TE2000-S (Nikon, Tokyo, Japan) microscopes.
Immunohistochemistry
For light microscopic examination, samples of the right lung
and the heart of six rats were obtained from each group.
The samples were fixed in formalin and embedded in
paraffin, and 4-mm sections were mounted onto Superfrost
slides. The right lung and heart sections were stained with
H&E to assess vascular and cardiac morphology. In each
group, medial thickness (micrometer) and medial wall area
(calculated as the area between the internal elastic lamina
and the adventitia in micrometer) of the muscular layer of
pulmonary arteries were determined using an Eclipse
TE2000-S microscope (Nikon) coupled to a color video
camera (Nikon). The relative weight ratio (i.e., right heart
index) is calculated as follows:
Relative weight ratioZright ventricleðRVÞ=
left ventricleðLVÞ þ intraventricular septumðSÞ ½2
The relative weight ratio was demonstrated by RV/left
ventricle þ septum (RV/LV þ S) using H&E staining. Mea-
surements were obtained using HistoLab software (GT
Vision Ltd, Haverhill, UK). Six PA measurements in each
animal were taken on average. The eNOS antibody (1:100)
was selected to carry out immunostaining on the right lung
sections.
Plasma concentrations of ET-1
The plasma concentration of ET-1 was determined using an
enzyme immunoassay kit according to the manufacturer’s
instructions (Biomedica Group, Wien, Austria). Cardiac
needle puncture (19 G) was performed to obtain blood,
followed by centrifugation for plasma sampling. Plasma
samples (0.8e1.0 mL) were acidified with 0.6% trifluoro-
acetic acid and centrifuged (2000g, 4C for 15 minutes).
Plasma concentrations of KMUP-1
The plasma concentrations of KMUP-1 (lower range:
0.1e20 ng/mL and higher range: 10e5000 ng/mL) in rats
receiving 3.6 mg/kg KMUP-1$HCl dissolved in propylene
glycol (25 mL) sublingually administered with a micropipette
were measured by the liquid chromatography-tandem mass
spectrometry method. In high-performance liquid chroma-
tography conditionsdmobile phase, 23% CH3CN þ 1%
HCOOH; column, Luna C18, 2.0 mm  50 mm, 5 mm (Phe-
nomenex, Torrance, CA, USA); and flow rate, 0.2 mL/
minutedmeasurements were carried out using a mass
spectrometer (Quattro Ultima, Micromass Ltd., Manchester,
UK), concomitantly using an autosampler (Waters Alliance
2790 LC, Waters, MA, USA) and data processor (MassLynx
Endothelin-1 and pulmonary hypertension 271version 3.5; Micromass Ltd.). Plasma concentrations were
measured at 0 minutes, 2 minutes, 5 minutes, 10 minutes,
and at 0.25 hours, 0.5 hours, 1 hour, 1.5 hours, 2 hours,
4 hours, 6 hours, 9 hours, and 24 hours.
Statistical analyses
The values are expressed as the mean  standard error of
the mean. The significance of difference was calculated by
Dunnett’s test. A p value <0.05 was taken to be significant.
Results
MPAP, MABP, and body weight
As shown in Table 1, the MPAP of normal control rats (Group
1) was 12.9  0.9 mmHg (nZ 6). This value sharply shifted
to 30.9  2.9 mmHg (nZ 6) in MCT-treated rats (Group 2).
After long-term treatment of MCT-treated rats with sub-
lingual KMUP-1 (2.5 mg/kg/day) or sildenafil (2.5 mg/kg/
day) for 21 days, PAH was markedly attenuated to
16.9  1.1 mmHg (Group 3) and 19.8  0.7 mmHg (Group 4;
n Z 6) on the last day, respectively. MABP and heart rate
were not significantly changed after treatment with KMUP-
1 or sildenafil. Body weight after treatment with KMUP-1
and sildenafil was increased from 310  5.6 g (Group 2) to
334  4.5 g (Group 3) and 328.6  8.3 g (Group 4),
respectively, compared with 373  5.4 g in nontreated rats
(Group 1).
MCT-induced MPAP was significantly reversed by treat-
ment with sublingual KMUP-1 and sildenafil (p < 0.05,
treatment vs. MCT). KMUP-1 was more potent than silden-
afil for inhibiting MCT-induced MPAP.
PA contractility
The concentration-dependent effects of KMUP-1
(0.1e100 mM) on ET-1-induced vascular constriction were
examined in endothelium-intact (Fig. 1A) and endothelium-
denuded (Fig. 1B) PA preparations from control rats or PA
preparations (Fig. 1C) from MCT-treated rats. KMUP-1
concentration dependently inhibited ET-1-induced
constriction in endothelium-intact PA preparations. In
endothelium-denuded PA, KMUP-1 at concentrations from
0.1 mM to 10 mM failed to inhibit ET-1-induced constriction.
At 100 mM, KMUP-1 sharply inhibited ET-1-inducedTable 1 Effects on MCT-induced body weight, MABP, heart rate
Groups Body weight (g) MABP (mmH
CTL 373  5.4 109  4.
MCT 310  5.6* 102.7  7.
MCT þ KMUP-1 334  4.5** 101  3.
MCT þ sildenafil 328.6  8.3** 105.2  4.
Data are presented as mean  standard error of the mean.
CTL Z control; MABP Z mean artery blood pressure; MCT Z monocr
*p < 0.05, compared with the CTL group.
**p < 0.05, compared with the MCT group (analysis of variance follow
a Effects on body weight, MABP, heart rate, and MPAP in rats treated
injection sharply increased MPAP levels, and sublingual administratioconstriction of endothelium-denuded PAs. In PAs from
MCT-treated rats, KMUP-1-induced relaxation was reduced
compared with non-MCT controls (Fig. 1C vs. Fig. 1A). L-
NAME pretreatment did not alter the response of PAs from
MCT rats to ET-1 and KMUP-1 (Fig. 1C and D), indicating
endothelium dysfunction in PAs from MCT rats. The esti-
mated inhibition of ET-1-induced PA contractility is shown
in Fig. 1E.
Pulmonary vascular wall thickening and H&E
staining
The PA wall thickness (%) of MCT-treated rats was measured
on Day 0 and Day 21 following right lung resection. As shown
in Fig. 2A, sections stained with H&E indicated that mus-
cularization of the distal PA was significantly lower in MCT-
treated rats that were given KMUP-1 (Group 3) or sildenafil
(Group 4), compared with vehicle only (Group 2). Results
showed that small pulmonary arterial morphology was
highly improved in KMUP-1-treated rats (Fig. 2B).
Immunohistochemical staining of eNOS
Morphometric immunostaining of Group 2 lung sections
demonstrated a marked decrease of eNOS mainly in the PA
endothelium, correlated with thickening. Treatments with
KMUP-1 or sildenafil restored eNOS immunostaining. The
negative control did not display brown endothelium stain-
ing (Fig. 2C).
PAH-associated RVH
MCT injection increased the relative weight and area of the
rat RV/LV þ S ratio, that is, the right heart weight index and
area index, to 40.9%  4.5% and 35.2%  1.7%, respectively
(Group 2) compared with normal rats (Group 1; Fig. 3A and
B). KMUP-1 reduced the right heart weight index to
30.6  1.8% (Group 3; Fig. 3A; p < 0.05, vs. MCT). Sildenafil
decreased the right heart weight index to 31.1  2.7%
(Group 4; Fig. 3A; p < 0.05, vs. MCT).
Expression of ET-1, ROCKII, eNOS, sGC1a, and PKG
Changes in ET-1 expression are shown in Fig. 4A. We found
that MCT induced significant ET-1 expression in lung pa-
renchyma tissue compared with the control group. Both, and MPAP of rats treated with KMUP-1 and sildenafil.a
g) Heart rate (beats/min) MPAP (mmHg)
4 375  25 12.9  0.9
0 354  37 30.9  2.9*
8 370  18 16.9  0.1**
0 381  22 19.8  0.9
otaline; MPAP Z mean pulmonary arterial pressure.
ed by Bonferroni test; n Z 6).
with MCT, MCT þ KMUP-1 or MCT þ sildenafil at Day 21: The MCT
n of KMUP-1 (2.5 mg/kg/day) markedly improved MPAP.
Figure 1. (A) Representative recording trace of KMUP-1 effects on ET-1-induced changes (%) in endothelium-intact (Eþ) PA
tension. (B) Representative recording trace of KMUP-1 effects on ET-1-induced changes (%) in endothelium-denuded (E) PA
tension. (C) Representative recording trace of KMUP-1 effects on ET-1-induced changes (%) in PA tension treated with MCT. (D)
Representative recording trace of KMUP-1 effects on ET-1-induced changes (%) in PA tension pretreated with L-NAME. (E) Effects of
KMUP-1 on ET-1-induced maximal PA contractility. The basal levels of tension were all adjusted to 1 g; ET-1 was added to produce
maximal constriction, and then a series of KMUP-1 concentrations were added into the organ bath. Bar chart represents the
mean  standard error of the mean of six experiments. ET-1 Z endothelin-1; L-NAME Z L-NG-nitroarginine methyl ester;
MCT Z monocrotaline; PA Z pulmonary artery.
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caused by MCT. Expression of ROCKII was increased to
354.3  80.1% in MCT-treated rats after 21 days. Treat-
ment with KMUP-1 and sildenafil during this period
reduced the increase of ROCKII to 150.2  29.5% and
97.1  28.8%, respectively (Fig. 4B). KMUP-1 was not
significantly different from sildenafil for decreasing ROCKII
expression.
As shown in Fig. 4C and D, Western blotting analysis
demonstrated that eNOS and sGC1a in lung tissues of MCT-
treated rats were increased by KMUP-1 to 315.5  67.3%
and 203.4  36.7% (Group 3) and by sildenafil to
180.35  37.4% and 109.2  22.2% (Group 4), respectively.
KMUP-1 was more potent than sildenafil in increasing the
expressions of eNOS and sGC. In addition, KMUP-1 increased
PKG to 140.3  20.8% (Group 3) more potently than sil-
denafil 76.6  13.8% (Group 4), compared with the non-
treated rats (Group 2; Fig. 4E).RhoA inactivation
Fig. 5A shows that KMUP-1 inhibited RhoA activation in
PASMCs in a concentration-dependent manner. RhoA acti-
vation was examined by measuring GTP-bound RhoA (active
RhoA) using Western blot in whole-cell lysates. Input RhoA
served as a loading control. Accordingly, RhoA activationwas directly inhibited by KMUP-1 in PASMCs treated for
24 hours.
ET-1-induced RhoA activation
Fig. 5B shows that ET-1 (0.01 mM) induced RhoA activation
in cultured PASMCs. RhoA activation was raised in cells
stimulated with ET-1 for 30 minutes compared with control
cells (p < 0.05). Pretreatment of PASMCs with KMUP-1
(0.1 mM, 1.0 mM, and 10 mM) for 24 hours also
concentration-dependently suppressed ET-1-induced RhoA
activation, which was fully achieved at 10 mM.
Plasma ET-1
Changes in ET-1 plasma concentration due to MCT injection
and treatment with KMUP-1 are shown in Fig. 6. The
MCT þ KMUP-1 group (Group 3) displayed a lower level of
ET-1 (0.05  0.02 ng/mL), compared with the MCT-treated
group (Group 2; 0.16  0.06 ng/mL), but higher than the
control group (Group 1; 0.007  0.002 ng/mL).
Plasma KMUP-1
Changes in KMUP-1 plasma concentration are shown in
Fig. 7A and B. Sample concentrations below 0.1 ng/mL
Figure 2. Effects of KMUP-1 and sildenafil on (A) pulmonary vascular morphology, (B) wall thickness, (C) eNOS immunoreactivity.
After intraperitoneal administration of MCT (60 mg/kg), KMUP-1 and sildenafil (2.5 mg/kg) were administered once daily for
21 days. PAs were stained with hematoxylineeosin (A) for eNOS immunoreactivity (brown) in PA endothelium (C). Scale bar Z (A)
100 mm and (C) 20 mm. Bar chart represents the mean  standard error of the mean of six experiments. *p < 0.05, compared with
CTL, and **p < 0.05, compared with MCT (analysis of variance followed by Bonferroni test). CTL Z control; eNOS Z endothelial
nitric oxide synthase; MCT Z monocrotaline-treated group; MCT þ KMUP-1 Z rats treated with MCT and KMUP-1;
MCT þ sildenafil Z rats treated with MCT and sildenafil; negative CTL Z control rats without immunostaining; PA Z pulmonary
artery.
Endothelin-1 and pulmonary hypertension 273were reported as below the lower limit of quantification.
The concentration was detectable within 6 hours, maxi-
mally at 0.25 hours, and trace KMUP-1 was found at
24 hours.Figure 3. Effects of KMUP-1 and sildenafil on MCT-induced RVH.
induced RVH represented by weight ratio. KMUP-1 or sildenafil was
day). Bar chart represents the mean  standard error of the mean
compared with MCT (analysis of variance followed by Bonferroni
treated with monocrotaline; MCT þ KMUP-1Z MCT rats treated with
21 days; RV Z right ventricle; RVH Z right ventricular hypertrophDiscussion
KMUP-1 inhibits PAH by increasing eNOS, sGC, and PKG and
decreasing ROCKII and ET-1 expression in MCT-treated rat(A) MCT þ sildenafil. (B) KMUP-1 and sildenafil improved MCT-
sublingually administered once daily for 3 weeks (2.5 mg/kg/
of six experiments. *p < 0.01, compared with CTL; **p < 0.01,
test). CTL Z control group; LV Z left ventricle; MCT Z rats
KMUP-1; MCT þ sildenafilZ MCT rats treated with sildenafil at
y; S Z septum.
Figure 4. Effects of KMUP-1 and sildenafil on MCT-induced expression of (A) ET-1, (B) ROCKII, (C) eNOS, (D) sGC, and (E) PKG in
lung tissues. Each value represents the mean  standard error of the mean of six experiments. *p < 0.05, compared with CTL;
**p < 0.01 and ***p < 0.001, compared with MCT; #p < 0.05, compared with MCT þ sildenafil (analysis of variance followed by
Dunnett’s test). CTLZ normal control group; ET-1Z endothelin-1; eNOSZ endothelial nitric oxide synthase; MCTZ rats treated
with monocrotaline; MCT þ KMUP-1Z rats treated with MCT and KMUP-1; MCT þ sildenafilZ rats treated with MCT and sildenafil;
PKG Z protein kinase G; ROCKII Z Rho kinase II; sGC Z soluble guanylate cyclase.
274 C.-P. Liu et al.lung tissue, vascular hyperplasia, and RVH. Three treat-
ment strategies for PAH are addressed in this study,
namely: (1) activating eNOS/sGC to accumulate cGMP or
increase PKG, targeting vascular relaxation [1]; (2) inhib-
iting ROCKII to desensitize Ca2þ, targeting the reduction of
vascular resistance [30]; and (3) inhibiting the activity of
ET-1 to attenuate PA constriction, targeting the reduction
of vascular constriction [5]. We measured the effects of
KMUP-1 and sildenafil on MCT-induced PAH and related
expression of eNOS, sGC, PKG, ROCKII, and ET-1, which are
linked to PA function. Inhibition combined with ET-1, 5-HT,
and a1A/1D receptors suggests that KMUP-1 is a GPCRs
antagonist inhibiting PAH and related RhoA/ROCK activa-
tion [1,2,31,32].
KMUP-1 in MCT-treated rats is suggested to activate
upstream eNOS and sGC by NO and to reduce downstream
ROCK expression or RhoA activation in the cGMP pathway.
PAH is partly attributed to impairment of cGMP/PKG
signaling, involving increased ROCK expression to retard
PKG-induced vasodilatation in hypoxia [33]. Downstream ofthe cGMP pathway, phosphorylation of RhoA interferes with
ROCK and phosphorylation of inositol 1, 4, 5-trisphosphate
(IP3) receptor-associated cGMP kinase substrate (IRAG) in-
hibits IP3/IRAG-mediated Ca2þ release from endoplasmic
reticulum [1,34e37]. Increased expression of ROCK is
associated with vascular resistance, which is attributed to
Ca2þ sensitization [16]. KMUP-1 may attenuate MCT-
induced PAH through the activation of eNOS and the inhi-
bition of ROCK-associated Ca2þ desensitization in PASMCs.
We demonstrated that the pharmacological activity of
KMUP-1 is more potent than sildenafil in enhancing the
expressions of eNOS, sGC, and PKG, and therefore KMUP-1
could be of greater benefit for inhibiting MCT-induced
pulmonary vascular thickness and RVH. However, further
investigations are needed in this regard.
L-NAME blocked the relaxation of the PA by KMUP-1 after
ET-1-induced constriction, exposing the important role of
eNOS expression and ET-1 in the PA. Western blotting an-
alyses of ET-1 and eNOS in lung tissue, morphologic immu-
nostaining of eNOS, and measurement of ET-1
Figure 5. Effects of KMUP-1 on RhoA-activation and ET-1-induced RhoA activation in pulmonary artery smooth muscle cells.
(A) Activation of RhoA was measured by GTP-bound RhoA (active RhoA) using Western blotting analysis of whole-cell lysates. (B)
Rho GTP is expressed as percentage of total RhoA density. Each value represents the mean  standard error of the mean of six
experiments. *p < 0.05, compared with CTL; **p < 0.01, compared with KMUP-1 at 0 mM; ***p < 0.01, compared with CTL
(analysis of variance followed by Dunnett’s test). CTL Z normal control group; ET-1 Z endothelin-1; GTP Z guanosine
triphosphate.
Endothelin-1 and pulmonary hypertension 275concentration in plasma confirm their interactive roles in
PA endothelium. By preventing elevated ET-1 and sup-
pressing eNOS in the dysfunctional endothelium, KMUP-1 is
beneficial for inhibiting vascular constriction and PAH.
Activation of eNOS/NO enhances vascular relaxation andFigure 6. Effects of KMUP-1 on ET-1 concentration changes
in rat plasma obtained by cardiac puncture. Plasma concen-
tration was measured at 0 minutes, 2 minutes, 5 minutes,
10 minutes, and at 0.25 hours, 0.5 hours, 1 hour, 1.5 hours,
2 hours, 4 hour, 6 hours, and 9 hours. Data were demonstrated
at (A) 0e60 minutes and (B) 0e24 hours, using a statistical
software (SPSS version 12.0; SPSS Inc., Chicago, IL, USA).
Plasma concentrations of MCT  KMUP-1 are significantly
different from MCT. Each value represents the
mean  standard error of the mean (SEM) of six experiments.
*p < 0.05, compared with CTL. **p < 0.05, compared with MCT.
Bar represents the mean  SEM. CTL Z normal control group;
Conc. Z concentration; ET-1 Z endothelin-1; MCT Z rats
treated with monocrotaline; MCT þ KMUP-1 Z rats treated
with MCT and sublingual administration of KMUP-1 (3.6 mg/kg).can inhibit ET-1-induced PA constriction [5]. Sildenafil is
unable to inhibit the concentration of ET-1 in plasma [32].
Reports [17,27,32] on mRNA determination, morphologic
examination, aorta-banded operation, heart failure, hyp-
oxia and reoxygenation, and administration of MCT have
suggested that sildenafil does not decrease ET-1 concen-
tration or expression, unlike KMUP-1. This could be another
advantage of using KMUP-1 to treat PAH-induced vascular
resistance.
Endothelium dysfunction can signal eNOS reduction in
MCT-treated rats, such as the rarefaction of eNOS immu-
nostaining restored by KMUP-1. Therefore, eNOS expression
by KMUP-1 is suggested to increase the production and
bioavailability of endothelium-derived NO. ROCK is an
important therapeutic target in cardiovascular medicine
[15,30]. In the PA, ROCK and eNOS expression display a
counterregulation relationship in endothelium [38e41].
Upregulated eNOS and downregulated ROCKII/ET-1 in the
PA might be an important mechanism of action (Fig. 8)
underlying the cardiovascular protective effect of KMUP-1
in PAH and associated RVH [42,43].
The use of the PDE-5 inhibitor sildenafil to treat PAH by
enhancing cGMP in the PA encouraged us to use KMUP-1 as a
cGMP-dependent ROCK inhibitor [1,2]. Sildenafil has been
described as potentiating compensatory upregulation of
NO/cGMP signaling in hypoxic PAH, instead of PDE-5 inhi-
bition. PDE-5 was either unchanged in long-term hypoxia,
or even significantly decreased along with unchanged ac-
tivity [14,44]. In this study, we demonstrated that KMUP-1
enhances eNOS, but not PDE-5A, contributing to an in-
crease in PKG levels.
Both KMUP-1 and sildenafil preserve eNOS/sGC/PKG and
reduce ROCKII/ET-1 expression caused by MCT. KMUP-1
displays more potent eNOS/sGC/PKG expression than sil-
denafil in MCT-treated rats. Administration of KMUP-1 or
sildenafil can inhibit ET-1/ROCKII expression and enhance
the NO/cGMP pathway, displaying antiproliferation and
antihyperplasia activity in the PA. Similar to statins and
ROCK inhibitors, inhibition of ROCK by KMUP-1 in the
Figure 7. Changes of KMUP-1 concentration in blood after sublingual administration within (A) 60 minutes and (B) within
24 hours. Each value represents the mean  standard error of the mean of six experiments. Conc. Z concentration.
276 C.-P. Liu et al.endothelium might increase or activate eNOS expression
and sustain PA relaxation activity to arrest or reverse the
MCT-induced pathogenesis of PAH. KMUP-1 appears more
soluble than sildenafil and is more favorable for sublingual
administration to obtain an effective blood concentration.
Sublingual KMUP-1 inhibited ET-1 expression and ET-1Figure 8. Proposed mechanism of action of KMUP-1 on the PA in
upregulation of ET-1/ROCKII and downregulation of eNOS in the
ROCKII expression, and reduces expression and plasma concentra
dysfunction, vascular hyperplasia, and right ventricular hype
hydroxytryptamine receptor 2B-coupled eNOS (2), which is also in
mediated activation of GPCRs and reduce the downstream activa
through active oxygen species in PA endothelium and smooth mus
monophosphate; ET-1 Z endothelin-1; eNOS Z endothelial nit
MCTZ monocrotaline; PAZ pulmonary artery; PDE 5AZ phospho
sGC Z soluble guanylate cyclase.concentration in MCT-induced PAH. This fact encouraged us
to further investigate whether KMUP-1 directly inhibits ET-
1-induced GTP-RhoA in PASMCs. We found that KMUP-1
clearly inhibits the activation of RhoA in a concentration-
dependent fashion and also inhibits ET-1-induced activation
of RhoA in PASMCs. ROCK expression is also related to anlung tissues. MCT induced endothelial dysfunction, leading to
PA. Treatment with KMUP-1 activates NO/sGC/cGMP, inhibits
tions of ET-1, protecting tissue from MCT-induced endothelial
rtrophy. Both 5-HT and KMUP-1 activate endothelium 5-
creased by sildenafil. Both KMUP-1 and bosentan inhibit ET-1-
tion of RhoA/ROCK enhanced by MCT and associated hypoxia
cles. 5-HT Z 5-hydroxytryptamine; cGMP Z cyclic guanosine
ric oxide synthase; GPCRs Z G-protein coupled receptors;
diesterase 5A; PKGZ protein kinase G; ROCKIIZ Rho kinase II;
Endothelin-1 and pulmonary hypertension 277agonist activity of ET-1 on GPCR of the PA, associated with
PA remodeling and vascular hyperplasia caused by MCT
[5,31,34,35]. Similar to statins, KMUP-1 inhibits the ex-
pressions of both ROCKII activation and ET-1, demonstrating
GTP binding of RhoA and RhoA activation in PASMCs and
preventing the hyperplasia of the PA in PAH caused by MCT
[1,19,31,32].
Several studies suggest that RhoA/ROCK activation and
expression of ET-1 contribute to vasoconstriction as well as
proliferation of smooth muscle cells in chronic PAH. In
parallel, expression of eNOS contributes not only to the
local regulation of vascular smooth muscle tone but also to
the inhibition of ROCKII, leading to the reduction of cell
proliferation in smooth muscles [7,41,42]. PAH can lead to
RVH due to vascular resistance in the PA. In our preventive
study using MCT-treated rats, MPAP, RV divide, LV divide,
septum, and small pulmonary arterial morphologic changes
were highly improved in the treated rats. KMUP-1 causes
specific PA vasodilatation and has an antihyperplasia ef-
fect, leading to a significant decrease of MPAP. Therefore,
KMUP-1 inhibits PAH by a combination of cGMP-enhancing
and ET-1/ROCKII-reducing activity in the PA to inhibit
long-term MCT-induced PAH and associated RVH.
KMUP-1 has been described as an inhibitor of nonspecific
GPCRs [1e3]. ET-1 receptor belongs to the GPCRs family;
therefore, nonselective inhibition of GPCRs by KMUP-1 is
theoretically a reasonable way to inhibit ET-1-mediated
activation of GPCRs resulting in smooth muscle constric-
tion and RhoA activation in the PA. Because MABP and heart
rate were not significantly changed after KMUP-1 adminis-
tration, PAH inhibition by a GPCRs antagonist would be
useful for the treatment of PAH. Sublingual KMUP-1 was
well absorbed and showed pharmacologic benefits to
reduce the unfavorable release of ET-1 after MCT admin-
istration. KMUP-1 was able to prevent MCT-induced PAH and
ET-1 release. Sublingual administration of KMUP-1 is sug-
gested to provide better bioavailability than oral adminis-
tration for inhibiting ET-1 release, expression, and blood
concentration in the cardiac and pulmonary circulation
systems.
In conclusion, sublingual administration of KMUP-1 in-
hibits PAH and associated ventricular hypertrophy by sup-
pressing ET-1, inactivating RhoA/ROCK, and enhancing
eNOS/sGC/PKG expression. KMUP-1 is suggested to be a
GPCR antagonist, instead of an ET-1 receptor antagonist,
for inhibiting MCT-induced and ET-1-mediated PAH.Acknowledgments
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